[1] CASTIGLIONE V, AIMO A, VERGARO G, et al. Biomarkers for the diagnosis and management of heart failure[J]. Heart Fail Rev, 2022, 27(2):625-643. [2] 王华, 杨杰孚. 心力衰竭防治任重道远[J]. 中华全科医师杂志, 2023, 22(6) : 549-552. [3] SUN H, SAEEDI P, KARURANGA S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract, 2022, 183:109119. [4] ORCES C H, LORENZO C. Prevalence of prediabetes and diabetes among older adults in Ecuador: analysis of the SABE survey[J]. Diabetes Metab Syndr, 2018, 12(2):147-153. [5] GUGLIN M, LYNCH K, KRISCHER J. Heart failure as a risk factor for diabetes mellitus[J]. Cardiology, 2014, 129(2):84-92. [6] OHKUMA T, KOMORITA Y, PETERS S A E, et al. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals[J]. Diabetologia, 2019, 62(9):1550-1560. [7] MEHTA A, BHATTACHARYA S, ESTEP J, et al. Diabetes and heart failure: a marriage of inconvenience[J]. Clin Geriatr Med, 2020, 36(3):447-455. [8] INCIARDI R M, CLAGGETT B, GUPTA D K, et al. Cardiac structure and function and diabetes-related risk of death or heart failure in older adults[J]. J Am Heart Assoc, 2022, 11(6):e022308. [9] PATEL A, ADVANCE Collaborative Group, MACMAHON S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial[J].Lancet, 2007, 370(9590):829-840.[10] BAHIRU E, HSIAO R, PHILLIPSON D, et al. Mechanisms and treatment of dyslipidemia in diabetes[J]. Curr Cardiol Rep, 2021, 23(4):26. [11] Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial[J]. Lancet, 2011, 378(9808):2013-2020. [12] TAN Y, ZHANG Z, ZHENG C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence[J]. Nat Rev Cardiol, 2020, 17(9):585-607. [13] EL HAYEK M S, ERNANDE L, BENITAH J P, et al. The role of hyperglycaemia in the development of diabetic cardiomyopathy[J]. Arch Cardiovasc Dis, 2021, 114(11):748-760. [14] AON M A, TOCCHETTI C G, BHATT N, et al. Protective mechanisms of mitochondria and heart function in diabetes[J]. Antioxid Redox Signal, 2015, 22(17):1563-1586. [15] GU J, FAN Y Q, ZHANG J F, et al. Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension[J]. Hellenic J Cardiol, 2018, 59(2):91-97. |